Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial
- Posted on September 17, 2025
- By CNBC
- 3 Views
Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial
Eli Lilly said orforglipron was better at lowering blood sugar levels than Novo Nordisk's oral semaglutide, and helped patients lose more weight.
